<DOC>
	<DOC>NCT00742144</DOC>
	<brief_summary>This is an open-label study to evaluate safety, tolerability, efficacy and PK profile of ofatumumab monotherapy in Japanese follicular lymphoma (FL) or chronic lymphocytic leukemia (CLL) patients. subject will receive ofatumumab 8 weekly infusions.</brief_summary>
	<brief_title>Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>INCLUSION CRITERIA: Signed Informed Consent. Histologically confirmed relapsed or refractory CD20 positive FL grade 13a and 1 or more clearly demarcated lesions with a largest diameter = 1.5 cm, or CD5, CD19, CD20 and CD23 positive relapse or refractory CLL. Subjects must have adequate blood, liver, and kidney function. Subjects who passed the provided periods from the last anticancer treatments at screening ECOG Performance Status of 02 Life expectancy more than 24 weeks at screening EXCLUSION CRITERIA: Current and past malignancy other than FL and CLL within 5 years prior to screening. Known Richter's transformation Previous autologous stem cell transplantation within 24 weeks prior to screening Previous allogeneic stem cell transplantation Known CNS involvement History of significant cerebrovascular disease Current cardiac disease requiring medical treatment Chronic or ongoing active infectious disease requiring systemic treatment Patients with pleural effusion or ascites detectable by physical examination Positive serology test for any of HBsAg, antiHBc or antiHCV Known HIV positive Pregnant or lactating women Women of childbearing potential and male patients not willing to use adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>CD20 positive</keyword>
	<keyword>Chronic lymphocytic leukemia</keyword>
	<keyword>Follicular lymphoma</keyword>
	<keyword>GSK1841157</keyword>
	<keyword>Japanese patient</keyword>
	<keyword>Ofatumumab</keyword>
</DOC>